Overview

A Global Study to Assess the Effects of Osimertinib in Participants With EGFRm Stage IA2-IA3 NSCLC Following Complete Tumour Resection

Status:
Not yet recruiting

Trial end date:
2032-11-02

Target enrollment:

Participant gender:

Summary

This is a global study to assess the effects of osimertinib in participants with EGFRm stage IA2-IA3 non-small cell lung cancer following complete tumour resection.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Osimertinib